US FDA Plans Streamlining Infant Formula Approval Process To Expand Supply Chain

FDA “determined a more streamlined pathway” using information it's received for  products available under enforcement discretion “would help provide for the long-term availability and marketing of many” of those products.

• Source: Shutterstock

Results from the US Food and Drug Administration’s and manufacturers’ responses this year to an infant formula shortage pointed the agency to plan to streamline its procedures for allowing additional firms to market formula.

The agency on 6 July announced it has “determined that a more streamlined pathway” using information it has received for...

More from Supply Chain

More from HBW Insight

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

Health and Human Services secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Lupin Goes For Growth With Indian Consumer Health Spin-Off

 
• By 

With annual sales approaching $20m, LupinLife Consumer Healthcare has ambitious growth plans for the Indian OTC market.